Details of the Drug

General Information of Drug (ID: DM96SE0)

• Drug Name: Haloperidol
• Synonyms: Aldo; Aloperidin; Aloperidol; Aloperidolo; Aloperidon; Bioperidolo; Brotopon; Dozic; Dozix; Eukystol; Fortunan; Galoperidol; Haldol; Halidol; Halojust; Halol; Halopal; Haloperido; Haloperidolum; Halopidol; Halopoidol; Halosten; Keselan; Linton; Mixidol; Pekuces; Peluces; Peridol; Pernox; Serenace; Serenase; Serenelfi; Sernas; Sernel; Sigaperidol; Ulcolind; Uliolind; Vesalium; Aloperidolo [DCIT]; Aloperidolo [Italian]; Einalon S; Haldol La; Haldol Solutab; Lealgin compositum; Pms Haloperidol; H 1512; R 1625; Aloperidin (TN); Apo-Haloperidol; Bioperidolo (TN); Brotopon (TN); Dozic (TN); Duraperidol (TN); Einalon S (TN); Eukystol (TN); Haldol (TN); Haloperidolum [INN-Latin]; Halosten (TN); Keselan (TN); Linton (TN);Novo-Peridol; Peluces (TN); R-1625; Serenace (TN); Serenase (TN); Sigaperidol (TN); Haloperidol (JP15/USP); McN-JR-1625; Haloperidol (JP15/USP/INN); Haloperidol [USAN:INN:BAN:JAN]

Indication

Disease Entry	ICD 11	Status	REF
Delirium	N.A.	Approved	[1]
Nausea	MD90	Approved	[1]
Psychotic disorder	6A20-6A25	Approved	[1]
Schizophrenia	6A20	Approved	[2]
Vomiting	MD90	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[3]
Tourette syndrome	8A05.00	Investigative	[1]

• Therapeutic Class: Antipsychotic Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  N05AD01: Haloperidol
  N05AD: Butyrophenone derivatives
  N05A: ANTIPSYCHOTICS
  N05: PSYCHOLEPTICS
  N: NERVOUS SYSTEM
  N05AD01: Haloperidol
  N05AD: Butyrophenone derivatives
  N05A: ANTIPSYCHOTICS
  N05: PSYCHOLEPTICS
  N: NERVOUS SYSTEM
  N05AD01: Haloperidol
  N05AD: Butyrophenone derivatives
  N05A: ANTIPSYCHOTICS
  N05: PSYCHOLEPTICS
  N: NERVOUS SYSTEM
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 375.9
  Logarithm of the Partition Coefficient (xlogp); 3.2
  Rotatable Bond Count (rotbonds); 6
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
  Bioavailability: 60% of drug becomes completely available to its intended biological destination(s) [5]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 7.8 mL/min/kg [6]
  Elimination: 1% of drug is excreted from urine in the unchanged form [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 35 hours [6]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.57 micromolar/kg/day [7]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.08% [6]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 17 L/kg [6]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.037 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Apoptosis	Not Available	MAPK14	OT5TCO3O	[8]
Apoptosis	Not Available	MAPK8	OTEREYS5	[8]
Orofacial dyskinesia	Not Available	SOD1	OT39TA1L	[8]
Orofacial dyskinesia	Not Available	CAT	OTHEBX9R	[8]
Parkinsonism	Not Available	MT-ND1	OTCLGIXV	[8]
Seizures (incl subtypes)	Not Available	KCNJ3	OTHQG16J	[8]
Tardive dyskinesia	Not Available	SLC6A4	OT6FGDLW	[8]

• Chemical Identifiers:
  Formula: C21H23ClFNO2
  IUPAC Name: 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
  Canonical SMILES: C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
  InChI: InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
  InChIKey: LNEPOXFFQSENCJ-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 3559
  ChEBI ID: CHEBI:5613
  CAS Number: 52-86-8
  UNII: J6292F8L3D
  DrugBank ID: DB00502
  TTD ID: D0D1AL
  VARIDT ID: DR00426
  INTEDE ID: DR0801
  ACDINA ID: D00310
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[9]
HUMAN opioid receptor sigma 1 (OPRS1)	TTTPE1L	SGMR1_HUMAN	Modulator	[10]
HUMAN sigma intracellular receptor 2 (TMEM97)	TTIS0R2	SGMR2_HUMAN	Modulator	[10]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[11]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[12]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[13]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[14]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[14]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[14]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[14]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[12]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[15]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Substrate	[16]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Gene/Protein Processing	[17]
5-hydroxytryptamine receptor 2A (HTR2A)	OTWXJX0M	5HT2A_HUMAN	Protein Interaction/Cellular Processes	[18]
Acetyl-CoA acetyltransferase, mitochondrial (ACAT1)	OTJC60Q7	THIL_HUMAN	Gene/Protein Processing	[19]
Alpha-1-antichymotrypsin (SERPINA3)	OT9BP2S0	AACT_HUMAN	Gene/Protein Processing	[20]
AP-2 complex subunit mu (AP2M1)	OTQCOSFN	AP2M1_HUMAN	Gene/Protein Processing	[19]
AP-3 complex subunit beta-1 (AP3B1)	OTYTIH5Q	AP3B1_HUMAN	Gene/Protein Processing	[19]
Asparagine synthetase (ASNS)	OT8R922G	ASNS_HUMAN	Gene/Protein Processing	[20]
Aspartyl/asparaginyl beta-hydroxylase (ASPH)	OT3KGDEE	ASPH_HUMAN	Gene/Protein Processing	[19]
ATP-dependent DNA/RNA helicase DHX36 (DHX36)	OT8IGL9Y	DHX36_HUMAN	Gene/Protein Processing	[19]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[21]

Molecular Expression Atlas of This Drug

• ICD Disease Classification: 06 Mental, behavioural or neurodevelopmental disorder
• Disease Class: ICD-11: 6A20 Schizophrenia
• The Studied Tissue: Pre-frontal cortex
• The Studied Disease: Schizophrenia [ICD-11:6A20]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	9.39E-01	-0.01	-0.05
Dopamine D2 receptor (D2R)	DTT	DRD2	9.91E-01	-0.02	-0.28
P-glycoprotein 1 (ABCB1)	DTP	P-GP	1.19E-01	-1.32E-01	-2.77E-01
P-glycoprotein 1 (ABCB1)	DTP	P-GP	1.65E-01	-1.47E-01	-4.48E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	6.73E-02	6.49E-02	3.07E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	6.45E-01	2.07E-02	1.74E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	1.17E-01	-3.87E-02	-2.23E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.74E-01	7.48E-03	1.37E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	7.39E-01	1.54E-02	4.74E-02
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	4.64E-02	-8.21E-02	-7.11E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	2.59E-01	6.29E-02	3.14E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	4.84E-01	-8.38E-02	-8.46E-01
Cytochrome P450 1A1 (CYP1A1)	DME	CYP1A1	2.32E-01	-3.66E-02	-1.30E-01
Cytochrome P450 1A1 (CYP1A1)	DME	CYP1A1	6.55E-01	1.27E-02	8.44E-02
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	8.99E-01	-6.93E-03	-1.36E-02
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	9.21E-01	7.31E-03	6.10E-02
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	4.66E-01	4.25E-02	1.20E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	4.75E-01	5.15E-02	3.64E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Haloperidol

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Quetiapine.	Schizophrenia [6A20]	[22]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Mesoridazine.	Schizophrenia [6A20]	[22]
Thioridazine	DM35M8J	Major	Decreased metabolism of Haloperidol caused by Thioridazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[23]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Aripiprazole.	Schizophrenia [6A20]	[24]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Iloperidone.	Schizophrenia [6A20]	[22]
Paliperidone	DM7NPJS	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Paliperidone.	Schizophrenia [6A20]	[22]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Molindone.	Schizophrenia [6A20]	[24]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Thiothixene.	Schizophrenia [6A20]	[24]
Trifluoperazine	DMKBYWI	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Trifluoperazine.	Schizophrenia [6A20]	[22]
Risperidone	DMN6DXL	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Risperidone.	Schizophrenia [6A20]	[22]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Amisulpride.	Schizophrenia [6A20]	[22]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Asenapine.	Schizophrenia [6A20]	[22]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Pimozide.	Schizophrenia [6A20]	[25]

Coadministration of a Drug Treating the Disease Different from Haloperidol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Ivosidenib.	Acute myeloid leukaemia [2A60]	[26]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Midostaurin.	Acute myeloid leukaemia [2A60]	[22]
Idarubicin	DMM0XGL	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Idarubicin.	Acute myeloid leukaemia [2A60]	[22]
Daunorubicin	DMQUSBT	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Daunorubicin.	Acute myeloid leukaemia [2A60]	[22]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Haloperidol and Oliceridine.	Acute pain [MG31]	[27]
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Scopolamine.	Addictive disorder [6C50-6C5Z]	[24]
Mitotane	DMU1GX0	Major	Increased metabolism of Haloperidol caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[28]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[29]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[29]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Memantine.	Alzheimer disease [8A20]	[24]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Haloperidol when combined with Rivastigmine.	Alzheimer disease [8A20]	[30]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Haloperidol when combined with Donepezil.	Alzheimer disease [8A20]	[30]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Haloperidol and Metronidazole.	Amoebiasis [1A36]	[31]
Isosorbide dinitrate	DMBI4JG	Moderate	Additive hypotensive effects by the combination of Haloperidol and Isosorbide dinitrate.	Anal fissure/fistula [DB50]	[32]
Trimethaphan	DMHF4IQ	Moderate	Additive hypotensive effects by the combination of Haloperidol and Trimethaphan.	Aneurysm/dissection [BD50]	[33]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Ivabradine.	Angina pectoris [BA40]	[25]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Dronedarone.	Angina pectoris [BA40]	[22]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Haloperidol and Amyl nitrite.	Angina pectoris [BA40]	[32]
Nifedipine	DMSVOZT	Moderate	Additive hypotensive effects by the combination of Haloperidol and Nifedipine.	Angina pectoris [BA40]	[32]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[22]
Hydroxyzine	DMF8Y74	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[22]
Cilostazol	DMZMSCT	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Cilostazol.	Arterial occlusive disease [BD40]	[22]
Voriconazole	DMAOL2S	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Voriconazole.	Aspergillosis [1F20]	[22]
Posaconazole	DMUL5EW	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Posaconazole.	Aspergillosis [1F20]	[22]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Levalbuterol.	Asthma [CA23]	[34]
Terbutaline	DMD4381	Major	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Terbutaline.	Asthma [CA23]	[35]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Pirbuterol.	Asthma [CA23]	[35]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Salbutamol.	Asthma [CA23]	[36]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[22]
Desipramine	DMT2FDC	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[37]
Ofloxacin	DM0VQN3	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Ciprofloxacin XR	DM2NLS9	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[22]
Clarithromycin	DM4M1SG	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[22]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Haloperidol and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[22]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[38]
Gemifloxacin	DMHT34O	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Norfloxacin	DMIZ6W2	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Levofloxacin	DMS60RB	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Lomefloxacin	DMVRH9C	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Telithromycin	DMZ4P3A	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Telithromycin.	Bacterial infection [1A00-1C4Z]	[22]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Retigabine.	Behcet disease [4A62]	[22]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Cariprazine.	Bipolar disorder [6A60]	[24]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Haloperidol and Loperamide.	Bowel habit change [ME05]	[39]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Eribulin.	Breast cancer [2C60-2C6Y]	[22]
Lapatinib	DM3BH1Y	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Lapatinib.	Breast cancer [2C60-2C6Y]	[22]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Haloperidol caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[40]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Toremifene.	Breast cancer [2C60-2C6Y]	[22]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Bosutinib.	Breast cancer [2C60-2C6Y]	[22]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Haloperidol when combined with Acetylcholine.	Cataract [9B10]	[41]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Haloperidol and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[22]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[42]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Haloperidol and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[35]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[34]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[42]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Haloperidol and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[35]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[42]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Haloperidol and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[35]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[35]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Haloperidol and Dihydrocodeine.	Chronic pain [MG30]	[43]
Oxaliplatin	DMQNWRD	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Oxaliplatin.	Colorectal cancer [2B91]	[22]
Isoproterenol	DMK7MEY	Major	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Isoproterenol.	Conduction disorder [BC63]	[35]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Haloperidol and Olopatadine.	Conjunctiva disorder [9A60]	[44]
Halothane	DM80OZ5	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Halothane.	Corneal disease [9A76-9A78]	[22]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Haloperidol and Propofol.	Corneal disease [9A76-9A78]	[45]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Sevoflurane.	Corneal disease [9A76-9A78]	[22]
Alfentanil	DMVO0UB	Major	Additive CNS depression effects by the combination of Haloperidol and Alfentanil.	Corneal disease [9A76-9A78]	[27]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Haloperidol and Remifentanil.	Corneal disease [9A76-9A78]	[27]
Probucol	DMVZQ2M	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Probucol.	Coronary atherosclerosis [BA80]	[22]
Dextromethorphan	DMUDJZM	Moderate	Decreased metabolism of Haloperidol caused by Dextromethorphan mediated inhibition of CYP450 enzyme.	Cough [MD12]	[31]
Clofazimine	DMEBOFW	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Clofazimine.	Crohn disease [DD70]	[22]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Mifepristone.	Cushing syndrome [5A70]	[22]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Pasireotide.	Cushing syndrome [5A70]	[22]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Osilodrostat.	Cushing syndrome [5A70]	[22]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Haloperidol caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[46]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Haloperidol due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[47]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Haloperidol and Ethanol.	Cystitis [GC00]	[44]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Haloperidol caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[48]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Haloperidol and Cyclandelate.	Dementia [6D80-6D8Z]	[32]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Haloperidol caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[49]
Sertraline	DM0FB1J	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Sertraline.	Depression [6A70-6A7Z]	[22]
Trimipramine	DM1SC8M	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Trimipramine.	Depression [6A70-6A7Z]	[37]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Cyclobenzaprine.	Depression [6A70-6A7Z]	[24]
Nortriptyline	DM4KDYJ	Major	Decreased metabolism of Haloperidol caused by Nortriptyline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[37]
Paroxetine	DM5PVQE	Moderate	Decreased metabolism of Haloperidol caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[50]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Escitalopram.	Depression [6A70-6A7Z]	[22]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Haloperidol and OPC-34712.	Depression [6A70-6A7Z]	[24]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Clomipramine.	Depression [6A70-6A7Z]	[37]
Trazodone	DMK1GBJ	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Trazodone.	Depression [6A70-6A7Z]	[22]
Amoxapine	DMKITQE	Major	Decreased metabolism of Haloperidol caused by Amoxapine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[37]
Doxepin	DMPI98T	Major	Decreased metabolism of Haloperidol caused by Doxepin mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[37]
Maprotiline	DMPWB7T	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Maprotiline.	Depression [6A70-6A7Z]	[22]
Nitroglycerin	DMQ2491	Moderate	Additive hypotensive effects by the combination of Haloperidol and Nitroglycerin.	Diabetic foot ulcer [BD54]	[32]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Mepenzolate.	Digestive system disease [DE2Z]	[24]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Oxybutynine.	Discovery agent [N.A.]	[24]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[51]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Meclizine.	Dizziness and giddiness [MB48]	[24]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Deutetrabenazine.	Dystonic disorder [8A02]	[52]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Ingrezza.	Dystonic disorder [8A02]	[22]
Zonisamide	DM0DTF7	Major	Increased risk of hyperpyrexia by the combination of Haloperidol and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[53]
Primidone	DM0WX6I	Major	Increased metabolism of Haloperidol caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[28]
Mephenytoin	DM5UGDK	Moderate	Antagonize the effect of Haloperidol when combined with Mephenytoin.	Epilepsy/seizure [8A61-8A6Z]	[25]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Haloperidol caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[54]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Haloperidol caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[28]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Haloperidol caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[25]
Ethotoin	DMXWOCP	Moderate	Antagonize the effect of Haloperidol when combined with Ethotoin.	Epilepsy/seizure [8A61-8A6Z]	[25]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Haloperidol caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[28]
Carbamazepine	DMZOLBI	Major	Increased metabolism of Haloperidol caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[28]
Diphenhydramine	DMKQTBA	Moderate	Antagonize the effect of Haloperidol when combined with Diphenhydramine.	Episodic vestibular syndrome [AB31]	[55]
Guanabenz	DM5QWEL	Moderate	Additive hypotensive effects by the combination of Haloperidol and Guanabenz.	Essential hypertension [BA00]	[32]
Ethacrynic acid	DM60QMR	Moderate	Additive hypotensive effects by the combination of Haloperidol and Ethacrynic acid.	Essential hypertension [BA00]	[33]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Haloperidol and Phenoxybenzamine.	Essential hypertension [BA00]	[32]
Nicardipine	DMCDYW7	Moderate	Additive hypotensive effects by the combination of Haloperidol and Nicardipine.	Essential hypertension [BA00]	[32]
Mecamylamine	DMGQFYB	Moderate	Additive hypotensive effects by the combination of Haloperidol and Mecamylamine.	Essential hypertension [BA00]	[32]
Benzthiazide	DMQWZ0H	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Benzthiazide.	Essential hypertension [BA00]	[31]
Nadolol	DMW6GVL	Moderate	Additive hypotensive effects by the combination of Haloperidol and Nadolol.	Essential hypertension [BA00]	[32]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Haloperidol caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[56]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Solifenacin.	Functional bladder disorder [GC50]	[22]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Haloperidol caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[57]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Tolterodine.	Functional bladder disorder [GC50]	[24]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Haloperidol caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[58]
Pentamidine	DMHZJCG	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Pentamidine.	Fungal infection [1F29-1F2F]	[22]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Haloperidol caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[59]
Ketoconazole	DMPZI3Q	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Ketoconazole.	Fungal infection [1F29-1F2F]	[22]
Amphotericin B	DMTAJQE	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Amphotericin B.	Fungal infection [1F29-1F2F]	[31]
Phentolamine	DMXYJOB	Moderate	Additive hypotensive effects by the combination of Haloperidol and Phentolamine.	Gangrene [MC85]	[32]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Propantheline.	Gastric ulcer [DA60]	[24]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[22]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[22]
Acetazolamide	DM1AF5U	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Acetazolamide.	Glaucoma [9C61]	[31]
Isoflurophate	DMBSK7X	Moderate	Antagonize the effect of Haloperidol when combined with Isoflurophate.	Glaucoma [9C61]	[41]
Carteolol	DMFMDOB	Moderate	Additive hypotensive effects by the combination of Haloperidol and Carteolol.	Glaucoma [9C61]	[32]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Haloperidol when combined with Pilocarpine.	Glaucoma [9C61]	[41]
Eplerenone	DMF0NQR	Moderate	Additive hypotensive effects by the combination of Haloperidol and Eplerenone.	Heart failure [BD10-BD1Z]	[32]
Carvedilol	DMHTEAO	Moderate	Additive hypotensive effects by the combination of Haloperidol and Carvedilol.	Heart failure [BD10-BD1Z]	[32]
Chlorothiazide	DMLHESP	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Chlorothiazide.	Heart failure [BD10-BD1Z]	[31]
Furosemide	DMMQ8ZG	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Furosemide.	Heart failure [BD10-BD1Z]	[31]
Amiloride	DMRTSGP	Moderate	Additive hypotensive effects by the combination of Haloperidol and Amiloride.	Heart failure [BD10-BD1Z]	[32]
Bumetanide	DMRV7H0	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Bumetanide.	Heart failure [BD10-BD1Z]	[31]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[31]
Isoniazid	DM5JVS3	Minor	Decreased metabolism of Haloperidol caused by Isoniazid.	HIV-infected patients with tuberculosis [1B10-1B14]	[60]
Rifampin	DMA8J1G	Major	Increased metabolism of Haloperidol caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[46]
Rifapentine	DMCHV4I	Major	Increased metabolism of Haloperidol caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[28]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Cobicistat	DM6L4H2	Moderate	Decreased clearance of Haloperidol due to the transporter inhibition by Cobicistat.	Human immunodeficiency virus disease [1C60-1C62]	[61]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[62]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[63]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Haloperidol caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[64]
Lopinavir	DMITQS0	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Haloperidol caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[65]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Haloperidol caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[66]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive hypotensive effects by the combination of Haloperidol and Isosorbide mononitrate.	Hydrocephalus [8D64]	[32]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Haloperidol caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[31]
Eprosartan	DM07K2I	Moderate	Additive hypotensive effects by the combination of Haloperidol and Eprosartan.	Hypertension [BA00-BA04]	[32]
Acebutolol	DM0TI4U	Moderate	Additive hypotensive effects by the combination of Haloperidol and Acebutolol.	Hypertension [BA00-BA04]	[32]
Moexipril	DM26E4B	Moderate	Additive hypotensive effects by the combination of Haloperidol and Moexipril.	Hypertension [BA00-BA04]	[32]
Bisoprolol	DM3UZ95	Moderate	Additive hypotensive effects by the combination of Haloperidol and Bisoprolol.	Hypertension [BA00-BA04]	[32]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Haloperidol and Captopril.	Hypertension [BA00-BA04]	[32]
Penbutolol	DM4ES8F	Moderate	Additive hypotensive effects by the combination of Haloperidol and Penbutolol.	Hypertension [BA00-BA04]	[32]
Clonidine	DM6RZ9Q	Moderate	Additive hypotensive effects by the combination of Haloperidol and Clonidine.	Hypertension [BA00-BA04]	[32]
Losartan	DM72JXH	Moderate	Additive hypotensive effects by the combination of Haloperidol and Losartan.	Hypertension [BA00-BA04]	[32]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Haloperidol and Nebivolol.	Hypertension [BA00-BA04]	[32]
Verapamil	DMA7PEW	Moderate	Additive hypotensive effects by the combination of Haloperidol and Verapamil.	Hypertension [BA00-BA04]	[32]
Pindolol	DMD2NV7	Moderate	Additive hypotensive effects by the combination of Haloperidol and Pindolol.	Hypertension [BA00-BA04]	[32]
Fenoldopam	DMFAOKP	Moderate	Additive hypotensive effects by the combination of Haloperidol and Fenoldopam.	Hypertension [BA00-BA04]	[32]
Indapamide	DMGN1PW	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Indapamide.	Hypertension [BA00-BA04]	[31]
Benazepril	DMH1M9B	Moderate	Additive hypotensive effects by the combination of Haloperidol and Benazepril.	Hypertension [BA00-BA04]	[32]
Trichlormethiazide	DMHAQCO	Moderate	Additive hypotensive effects by the combination of Haloperidol and Trichlormethiazide.	Hypertension [BA00-BA04]	[32]
Labetalol	DMK8U72	Moderate	Additive hypotensive effects by the combination of Haloperidol and Labetalol.	Hypertension [BA00-BA04]	[32]
Diazoxide	DML1538	Moderate	Additive hypotensive effects by the combination of Haloperidol and Diazoxide.	Hypertension [BA00-BA04]	[32]
Enalapril	DMNFUZR	Moderate	Additive hypotensive effects by the combination of Haloperidol and Enalapril.	Hypertension [BA00-BA04]	[32]
Perindopril	DMOPZDT	Moderate	Additive hypotensive effects by the combination of Haloperidol and Perindopril.	Hypertension [BA00-BA04]	[32]
Quinapril	DMR8H31	Moderate	Additive hypotensive effects by the combination of Haloperidol and Quinapril.	Hypertension [BA00-BA04]	[32]
Deserpidine	DMRH7CV	Moderate	Additive hypotensive effects by the combination of Haloperidol and Deserpidine.	Hypertension [BA00-BA04]	[32]
Telmisartan	DMS3GX2	Moderate	Additive hypotensive effects by the combination of Haloperidol and Telmisartan.	Hypertension [BA00-BA04]	[32]
Irbesartan	DMTP1DC	Moderate	Additive hypotensive effects by the combination of Haloperidol and Irbesartan.	Hypertension [BA00-BA04]	[32]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Haloperidol and Hydralazine.	Hypertension [BA00-BA04]	[32]
Lisinopril	DMUOK4C	Moderate	Additive hypotensive effects by the combination of Haloperidol and Lisinopril.	Hypertension [BA00-BA04]	[32]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[31]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Haloperidol and Clevidipine butyrate.	Hypertension [BA00-BA04]	[32]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Haloperidol caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[67]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Haloperidol caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[68]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[24]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Amantadine.	Influenza [1E30-1E32]	[69]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Haloperidol caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[70]
Propiomazine	DMKY8V1	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Propiomazine.	Insomnia [7A00-7A0Z]	[24]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Haloperidol and ITI-007.	Insomnia [7A00-7A0Z]	[24]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Haloperidol and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[22]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Phenolphthalein.	Irritable bowel syndrome [DD91]	[22]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Clidinium.	Irritable bowel syndrome [DD91]	[24]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Dicyclomine.	Irritable bowel syndrome [DD91]	[24]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Haloperidol when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[30]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Crizotinib.	Lung cancer [2C25]	[22]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Haloperidol caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[71]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Haloperidol and Porfimer Sodium.	Lung cancer [2C25]	[72]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Ceritinib.	Lung cancer [2C25]	[22]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Haloperidol caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[73]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Haloperidol caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[74]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Osimertinib.	Lung cancer [2C25]	[22]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Selpercatinib.	Lung cancer [2C25]	[22]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Lumefantrine.	Malaria [1F40-1F45]	[31]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Halofantrine.	Malaria [1F40-1F45]	[75]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Chloroquine.	Malaria [1F40-1F45]	[22]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Hydroxychloroquine.	Malaria [1F40-1F45]	[22]
Primaquine	DMWQ16I	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Primaquine.	Malaria [1F40-1F45]	[22]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[22]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Haloperidol caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[76]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Haloperidol caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[77]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[78]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Vemurafenib.	Melanoma [2C30]	[22]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Haloperidol and LGX818.	Melanoma [2C30]	[22]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Haloperidol caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[25]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Haloperidol and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[79]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Haloperidol and Lasmiditan.	Migraine [8A80]	[80]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Haloperidol caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[81]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Haloperidol and Flibanserin.	Mood disorder [6A60-6E23]	[82]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Panobinostat.	Multiple myeloma [2A83]	[83]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Haloperidol and Thalidomide.	Multiple myeloma [2A83]	[84]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Siponimod.	Multiple sclerosis [8A40]	[31]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Fingolimod.	Multiple sclerosis [8A40]	[22]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Ozanimod.	Multiple sclerosis [8A40]	[85]
Rifabutin	DM1YBHK	Major	Increased metabolism of Haloperidol caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[28]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Romidepsin.	Mycosis fungoides [2B01]	[22]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Haloperidol caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[25]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Nilotinib.	Myeloproliferative neoplasm [2A20]	[22]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Haloperidol caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[86]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Dasatinib.	Myeloproliferative neoplasm [2A20]	[22]
Dextroamphetamine	DMMIHVP	Moderate	Antagonize the effect of Haloperidol when combined with Dextroamphetamine.	Narcolepsy [7A20]	[87]
Modafinil	DMYILBE	Minor	Increased metabolism of Haloperidol caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[88]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Phenindamine.	Nasopharyngitis [CA00]	[24]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Dimenhydrinate.	Nausea/vomiting [MD90]	[24]
Promethazine	DM6I5GR	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Promethazine.	Nausea/vomiting [MD90]	[22]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Haloperidol caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[89]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Cyclizine.	Nausea/vomiting [MD90]	[24]
Metoclopramide	DMFA5MY	Major	Additive antidopaminergic effects by the combination of Haloperidol and Metoclopramide.	Nausea/vomiting [MD90]	[90]
Granisetron	DMIUW25	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Granisetron.	Nausea/vomiting [MD90]	[22]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Dolasetron.	Nausea/vomiting [MD90]	[22]
Ondansetron	DMOTQ1I	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Ondansetron.	Nausea/vomiting [MD90]	[22]
Bupropion	DM5PCS7	Major	Decreased metabolism of Haloperidol caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[22]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Entrectinib.	Non-small cell lung cancer [2C25]	[22]
Phendimetrazine	DM6TS1N	Moderate	Antagonize the effect of Haloperidol when combined with Phendimetrazine.	Obesity [5B80-5B81]	[87]
Amfepramone	DM9YSNQ	Moderate	Antagonize the effect of Haloperidol when combined with Amfepramone.	Obesity [5B80-5B81]	[87]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Haloperidol caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[91]
Benzphetamine	DMIJATC	Moderate	Antagonize the effect of Haloperidol when combined with Benzphetamine.	Obesity [5B80-5B81]	[87]
Mazindol	DMZ36RN	Moderate	Antagonize the effect of Haloperidol when combined with Mazindol.	Obesity [5B80-5B81]	[87]
Metolazone	DMB39LO	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Metolazone.	Oedema [MG29]	[31]
Polythiazide	DMCH80F	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Polythiazide.	Oedema [MG29]	[31]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Levomethadyl Acetate.	Opioid use disorder [6C43]	[25]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Lofexidine.	Opioid use disorder [6C43]	[22]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Haloperidol and Apraclonidine.	Optic nerve disorder [9C40]	[92]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Rucaparib.	Ovarian cancer [2C73]	[22]
Pentazocine	DM1XBHS	Major	Additive CNS depression effects by the combination of Haloperidol and Pentazocine.	Pain [MG30-MG3Z]	[27]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Haloperidol and Dextropropoxyphene.	Pain [MG30-MG3Z]	[93]
Butorphanol	DM5KYPJ	Major	Additive CNS depression effects by the combination of Haloperidol and Butorphanol.	Pain [MG30-MG3Z]	[27]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Haloperidol and Oxymorphone.	Pain [MG30-MG3Z]	[27]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Haloperidol and Levorphanol.	Pain [MG30-MG3Z]	[27]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Haloperidol and Dezocine.	Pain [MG30-MG3Z]	[27]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Flavoxate.	Pain [MG30-MG3Z]	[24]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Haloperidol and Nalbuphine.	Pain [MG30-MG3Z]	[27]
Methamphetamine	DMPM4SK	Moderate	Antagonize the effect of Haloperidol when combined with Methamphetamine.	Pain [MG30-MG3Z]	[94]
Buprenorphine	DMPRI8G	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Buprenorphine.	Pain [MG30-MG3Z]	[22]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Haloperidol and Hydrocodone.	Pain [MG30-MG3Z]	[27]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Triclabendazole.	Parasitic worm infestation [1F90]	[22]
Pergolide	DM14MAE	Moderate	Antagonize the effect of Haloperidol when combined with Pergolide.	Parkinsonism [8A00]	[95]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Haloperidol when combined with Opicapone.	Parkinsonism [8A00]	[95]
Biperiden	DME78OA	Moderate	Antagonize the effect of Haloperidol when combined with Biperiden.	Parkinsonism [8A00]	[55]
Levodopa	DMN3E57	Moderate	Antagonize the effect of Haloperidol when combined with Levodopa.	Parkinsonism [8A00]	[95]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Pimavanserin.	Parkinsonism [8A00]	[22]
Bromocriptine	DMVE3TK	Moderate	Antagonize the effect of Haloperidol when combined with Bromocriptine.	Parkinsonism [8A00]	[95]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Orphenadrine.	Parkinsonism [8A00]	[24]
Apomorphine	DMX38HQ	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Apomorphine.	Parkinsonism [8A00]	[22]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Haloperidol caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[96]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Methylscopolamine.	Peptic ulcer [DA61]	[24]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Haloperidol and Famotidine.	Peptic ulcer [DA61]	[31]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[97]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Lefamulin.	Pneumonia [CA40]	[98]
Hydrocortisone	DMGEMB7	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[31]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Haloperidol caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[99]
Ritodrine	DM4V6RL	Major	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Ritodrine.	Preterm labour/delivery [JB00]	[35]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Degarelix.	Prostate cancer [2C82]	[22]
ABIRATERONE	DM8V75C	Major	Increased risk of prolong QT interval by the combination of Haloperidol and ABIRATERONE.	Prostate cancer [2C82]	[22]
Nilutamide	DMFN07X	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Nilutamide.	Prostate cancer [2C82]	[22]
Enzalutamide	DMGL19D	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Enzalutamide.	Prostate cancer [2C82]	[22]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Relugolix.	Prostate cancer [2C82]	[22]
Bicalutamide	DMZMSPF	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Bicalutamide.	Prostate cancer [2C82]	[22]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Haloperidol and Terazosin.	Prostate hyperplasia [GA90]	[32]
Tamsulosin	DM5QF9V	Moderate	Additive hypotensive effects by the combination of Haloperidol and Tamsulosin.	Prostate hyperplasia [GA90]	[32]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Haloperidol and Silodosin.	Prostate hyperplasia [GA90]	[32]
Levomepromazine	DMIKFEL	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Levomepromazine.	Psychotic disorder [6A20-6A25]	[22]
Fluphenazine	DMIT8LX	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Fluphenazine.	Psychotic disorder [6A20-6A25]	[22]
Triflupromazine	DMKFQJP	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Triflupromazine.	Psychotic disorder [6A20-6A25]	[22]
Tolazoline	DMI40NL	Moderate	Additive hypotensive effects by the combination of Haloperidol and Tolazoline.	Pulmonary hypertension [BB01]	[32]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Haloperidol and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[100]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[22]
Neupro	DMHEAB1	Moderate	Additive CNS depression effects by the combination of Haloperidol and Neupro.	Restless legs syndrome [7A80]	[95]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Haloperidol and Fentanyl.	Sensation disturbance [MB40]	[27]
Sufentanil	DMU7YEL	Major	Additive CNS depression effects by the combination of Haloperidol and Sufentanil.	Sensation disturbance [MB40]	[27]
Vardenafil	DMTBGW8	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Vardenafil.	Sexual dysfunction [HA00-HA01]	[22]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Haloperidol caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[101]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Haloperidol caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[25]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Haloperidol caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[31]
Armodafinil	DMGB035	Minor	Increased metabolism of Haloperidol caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[88]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Haloperidol and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[22]
Cisplatin	DMRHGI9	Moderate	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Cisplatin.	Solid tumour/cancer [2A00-2F9Z]	[31]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[22]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[22]
Doxorubicin	DMVP5YE	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[22]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Pitolisant.	Somnolence [MG42]	[22]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[22]
Adenosine	DMM2NSK	Major	Increased risk of ventricular arrhythmias by the combination of Haloperidol and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[102]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Haloperidol due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[103]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Lenvatinib.	Thyroid cancer [2D10]	[22]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Cabozantinib.	Thyroid cancer [2D10]	[22]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Papaverine.	Tonus and reflex abnormality [MB47]	[104]
Tizanidine	DMR2IQ4	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Tizanidine.	Tonus and reflex abnormality [MB47]	[22]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Haloperidol and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[100]
Tacrolimus	DMZ7XNQ	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Tacrolimus.	Transplant rejection [NE84]	[22]
Atropine	DMEN6X7	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Atropine.	Unspecific substance harmful effect [NE6Z]	[24]
Astemizole	DM2HN6Q	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[22]
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[24]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[24]
Trimeprazine	DMEMV9D	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[22]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[24]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[24]
Azatadine	DMZ80SB	Moderate	Additive anticholinergic effects by the combination of Haloperidol and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[24]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Procainamide.	Ventricular tachyarrhythmia [BC71]	[22]
Propafenone	DMPIBJK	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Propafenone.	Ventricular tachyarrhythmia [BC71]	[22]
Flecainide	DMSQDLE	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Flecainide.	Ventricular tachyarrhythmia [BC71]	[22]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Haloperidol and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[22]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
D&C red no. 27	E00381	83511	Colorant
D&C red no. 30	E00456	3000709	Colorant
FD&C blue no. 1	E00263	19700	Colorant
Lactic acid	E00020	612	Acidulant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Brushite	E00392	104805	Diluent
Calcium stearate	E00244	15324	lubricant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Haloperidol 10 mg tablet	10 mg	Oral Tablet	Oral
Haloperidol 20 mg tablet	20 mg	Oral Tablet	Oral
Haloperidol 0.5 mg tablet	0.5 mg	Oral Tablet	Oral
Haloperidol 1 mg tablet	1 mg	Oral Tablet	Oral
Haloperidol 2 mg tablet	2 mg	Oral Tablet	Oral
Haloperidol 5 mg tablet	5 mg	Oral Tablet	Oral
Haloperidol Decanoate eq 50mg base/ml injectable	eq 50mg base/ml	Injectable	Injection

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Haloperidol FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 86).
• [3] Sigma-1Rs are upregulated via PERK/eIF2/ATF4 pathway and execute protective function in ER stress. Biochem Biophys Res Commun. 2011 Nov 25;415(3):519-25.
• [4] BDDCS applied to over 900 drugs
• [5] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [6] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [7] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [8] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [9] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [10] A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
• [11] Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
• [12] Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003 Mar;31(3):243-9.
• [13] Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
• [14] In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
• [15] Drug Interactions Flockhart Table
• [16] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [17] Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J. 2005;5(5):298-304.
• [18] Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12.
• [19] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [20] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [21] Reversal effect of haloperidol on doxorubicin resistance and chloride channel inhibition in erythroleukemic cell K562/Dox. Zhonghua Zhong Liu Za Zhi. 2005 Feb;27(2):81-5.
• [22] Canadian Pharmacists Association.
• [23] Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
• [24] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [25] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [26] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [27] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [28] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [29] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [30] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [31] Cerner Multum, Inc. "Australian Product Information.".
• [32] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [33] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
• [34] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [35] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [36] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
• [37] Alter P, Tontsch D, Grimm W "Doxepin-induced torsade de pointes tachycardia." Ann Intern Med 135 (2001): 384-5. [PMID: 11529713]
• [38] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [39] Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
• [40] Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
• [41] Multum Information Services, Inc. Expert Review Panel.
• [42] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [43] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [44] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [45] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [46] Cerner Multum, Inc "ANVISA Bulario Eletrnico." .
• [47] Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
• [48] Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
• [49] Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
• [50] Nicholson SD "Extra pyramidal side effects associated with paroxetine." West Engl Med J 107 (1992): 90-1. [PMID: 1308691]
• [51] Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
• [52] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [53] Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
• [54] Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
• [55] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
• [56] Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
• [57] Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
• [58] Yasui N, Kondo T, Otani K, Furukori H, Mihara K, Suzuki A, Kaneko S, Inoue Y "Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: In vivo evidence of the involvement of CYP3A4 for haloperidol metabolism." J Clin Psychopharmacol 19 (1999): 149-54. [PMID: 10211916]
• [59] AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
• [60] Takeda M, Nishinuma K, Yamashita S, et al "Serum haloperidol levels of schizophrenics receiving treatment for tuberculosis." Clin Neuropharmacol 9 (1986): 386-97. [PMID: 3731135]
• [61] Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
• [62] Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
• [63] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [64] Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
• [65] Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
• [66] Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
• [67] Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
• [68] Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
• [69] Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
• [70] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [71] Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [72] Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
• [73] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [74] Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [75] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [76] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [77] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [78] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [79] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [80] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [81] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [82] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [83] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [84] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [85] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [86] Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
• [87] Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
• [88] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [89] Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
• [90] Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
• [91] Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
• [92] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [93] Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
• [94] Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
• [95] Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
• [96] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [97] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [98] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [99] Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
• [100] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [101] Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
• [102] Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
• [103] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [104] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]